Clinical Research Directory
Browse clinical research sites, groups, and studies.
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Sponsor: Alnylam Pharmaceuticals
Summary
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Official title: TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
1750
Start Date
2025-07-02
Completion Date
2032-11-30
Last Updated
2026-10-20
Healthy Volunteers
No
Interventions
Nucresiran
Nucresiran 300 mg administered SC q6M
Sterile Normal Saline (0.9% NaCl)
Sterile Normal Saline (0.9% NaCl) administered SC once q6M
Locations (266)
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
Laguna Hills, California, United States
Clinical Trial Site
Stanford, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Clinical Trial Site
Norwich, Connecticut, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Brandon, Florida, United States
Clinical Trial Site
Miami, Florida, United States
Clinical Trial Site
Atlanta, Georgia, United States
Clinical Trial Site
Gainesville, Georgia, United States
Clinical Trial Site
Tucker, Georgia, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Evanston, Illinois, United States
Clinical Trial Site
Indianapolis, Indiana, United States
Clinical Trial Site
Indianapolis, Indiana, United States
Clinical Trial Site
Kansas City, Kansas, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Detroit, Michigan, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
Manhasset, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
The Bronx, New York, United States
Clinical Trial Site
Charlotte, North Carolina, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Columbus, Ohio, United States
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Lancaster, Pennsylvania, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Charleston, South Carolina, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Plano, Texas, United States
Clinical Trial Site
Salt Lake City, Utah, United States
Clinical Trial Site
Charlottesville, Virginia, United States
Clinical Trial Site
Falls Church, Virginia, United States
Clinical Trial Site
Norfolk, Virginia, United States
Clinical Trial Site
Richmond, Virginia, United States
Clinical Trial Site
Seattle, Washington, United States
Clinical Trial Site
Spokane, Washington, United States
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Córdoba, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Adelaide, Australia
Clinical Trial Site
Bedford Park, Australia
Clinical Trial Site
Box Hill, Australia
Clinical Trial Site
Chermside, Australia
Clinical Trial Site
Darlinghurst, Australia
Clinical Trial Site
Joondalup, Australia
Clinical Trial Site
Liverpool, Australia
Clinical Trial Site
Westmead, Australia
Clinical Trial Site
Braunau am Inn, Austria
Clinical Trial Site
Graz, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Wels, Austria
Clinical Trial Site
Aalst, Belgium
Clinical Trial Site
Bruges, Belgium
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Dendermonde, Belgium
Clinical Trial Site
Edegem, Belgium
Clinical Trial Site
Genk, Belgium
Clinical Trial Site
Ghent, Belgium
Clinical Trial Site
Hasselt, Belgium
Clinical Trial Site
Leuven, Belgium
Clinical Trial Site
Liège, Belgium
Clinical Trial Site
Roeselare, Belgium
Clinical Trial Site
Belo Horizonte, Brazil
Clinical Trial Site
Campinas, Brazil
Clinical Trial Site
Porto Alegre, Brazil
Clinical Trial Site
Porto Alegre, Brazil
Clinical Trial Site
Recife, Brazil
Clinical Trial Site
Ribeirão Preto, Brazil
Clinical Trial Site
Ribeirão Preto, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
Salvador, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
Calgary, Canada
Clinical Trial Site
London, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Vancouver, Canada
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Binhai, China
Clinical Trial Site
Changsha, China
Clinical Trial Site
Changsha, China